DOCSLIB.ORG

Download (142Kb)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download (142Kb) Volume 9 Supplement 1 July 2019 TALKS 13 Intracellular ion channels and transporters 15 RNA processing Table of Contents 16 Signal transduction PLENARY LECTURES 17 Mitochondria and signaling 18 DNA architecture Saturday 6 July 19 RNA transcription 3 Opening Plenary Lecture Monday 8 July Sunday 7 July 20 DNA editing and modification 3 IUBMB Lecture 22 RNA transport and translation 3 The FEBS Journal Richard Perham Prize Lecture 24 Single cell analysis and imaging 3 FEBS/EMBO Women in Science Award Lecture 25 Calcium and ROS signaling Monday 8 July 26 Sulfur metabolism and cellular regulation 27 Molecular neurobiology 4 FEBS Datta Lecture 29 RNA turnover 4 FEBS Sir Hans Krebs Lecture 30 Cytoskeleton and molecular mechanisms of motility Tuesday 9 July 31 Rare diseases 4 FEBS Theodor Bücher Lecture Tuesday 9 July 5 FEBS 2019 Plenary Lecture 32 Signaling in brain cancer Wednesday 10 July 34 Synthetic biopolymers for biomedicine 5 PABMB Lecture 35 Integrative approaches to structural and synthetic biology 5 EMBO Lecture 37 Induced pluripotent cells Thursday 11 July 39 Long noncoding RNA 40 Neurodegeneration 5 Closing Plenary Lecture 42 Cell therapy and regenerative medicine FEBS SPECIAL SESSIONS 44 Small noncoding RNA Sunday 7 July Wednesday 10 July 6 Gender issues in science 45 Proteins: structure, disorder and dynamics 47 Plant biotechnology Monday 8 July 48 Natural networks and systems 6 Education 1 – Creative teaching: effective learning in life sciences 50 RNA in pathogenesis and therapy education 51 Biochemistry, a success story Tuesday 9 July 52 Molecular biology of aging 7 Education 2 – Future education now! 53 Plant–environment interaction 7 Science and Society – Personalised medicine: a future vision 54 Synthetic networks and systems 55 Multicomponent complexes Wednesday 10 July Thursday 11 July 8 Research and career skills 57 Cell signaling in tumor biology SYMPOSIA 59 Bionanotechnology Sunday 7 July 60 Epigenetics and protein glycosylation 9 Molecular mechanism of inflammation-related diseases 61 Genome editing (CRISPR) 10 DNA variation 62 Proteomic technologies 12 Cardiovascular diseases Abstracts submitted to the 44th FEBS Congress, taking place in Krakow, Poland from 6th to 11th July 2019, and accepted by the Congress Organizing Committee are published in this Supplement of FEBS Open Bio. Late-breaking abstracts are not included in this issue. About these abstracts Abstracts submitted to the Congress are not peer-reviewed. In addition, abstracts are published as submitted and are not copyedited prior to publication. We are unable to make corrections of any kind to the abstracts once they are published. Indexing Abstracts published in FEBS Open Bio Supplement for the 44th FEBS Congress will be included individually in the Conference Proceedings Citation Index published by Web of Science. How to cite these abstracts AuthorOne, A., AuthorTwo, B. (2019). Abstract title. FEBS Open Bio, 9: Abstract number*. doi:10.1002/2211-5463.12674 * The Abstract number begins with the letters PL, SS, S or ShT and can be found atop each abstract’s title in the PDF file. FEBS Open Bio 9 (Suppl.1) (2019) 2–64 DOI: 10.1002/2211-5463.12674 2 © 2019 The Authors. FEBS Open Bio © 2019 FEBS FFEB4_v9_s1_12674.inddEB4_v9_s1_12674.indd 1 66/18/2019/18/2019 9:46:559:46:55 AAMM SYMPOSIA Thursday 11 July differential processing of proenkephalinergic and proopiome- ShT-39-1 lanocortin (POMC) systems among controls, prolactin-secreting Semi-targeted metabolomic studies of microadenomas, and non-secreting macroadenomas. We will pre- methamphetamine’s biotransformations and sent our discovery data on growth hormone (GH) isoforms, dif- ferentially expressed proteins (n = 56) between controls and its impact on macrophage’s secreted macroadenomas, novel phosphoproteins, and oxidative stress metabolome nitroproteins (NS). All of these data profoundly impact on our K. Pawlak1, K. Lech2, A. Vei3, A. Harwood3, P. Ciborowski3 knowledge of human neuroendocrinology. 1Faculty of Chemistry, Warsaw University of Technology, Warsaw, Poland, 2Faculty of Chemistry, Warsaw University of Technology, Warszawa, Poland, 3Department of Pharmacology S-39-3 and Experimental Neuroscience, University of Nebraska Medical Omics in precision medicine Center (UNMC), Omaha, United States of America J. Bergquist Methamphetamine (MA) is an illegal psychostimulant. Despite Analytical Chemistry and Neurochemistry, Department of the prevalence of MA addiction, its effect on the innate immune Chemistry – Biomedical Centre, Uppsala University, Uppsala, system is not known. Several reports showed the effect of MA on Sweden various aspects of intracellular signaling, yet changes in intracel- It has been estimated that only Alzheimer’s disease (AD) alone, lular and secreted metabolomes induced by MA in human mono- the most common form of dementia, will affect approximately 81 cyte derived macrophages (hMDM) has been understudied. In million individuals by 2040. To date, the actual cause and cascade this study, we used a semi-targeted metabolomic approach to of events in the progression of many neurological and neurodegen- investigate the effect of MA on macrophages secreted metabo- erative diseases have not been fully determined. Furthermore, there lism. Culture supernatants from hMDM exposed to MA or con- is no definitive blood test or simple diagnostic method for many trols were subjected to solid phase extraction (SPE, Plexa PCX) of those diseases so far available. Fibril formation of proteins, or liquid-liquid extraction and followed by reversed phase chro- together with a dysfunctional regulation of lipids and steroids, has matography performed with two columns connected in-line (EC been shown to play a fundamental role influencing various risk 50/2 Nucleodur C18 Pyramid, 3 lm and EC 150/2.1 Cogent, factors of neurodegeneration and pathogenesis. Recently, there has UDC-Cholesterol, 4 lm). A QTRAP 6500 MS/MS System with a been a stronger focus on proteomics and metabolomics (e.g. lipi- Turbo Spray ion source (SCIEX, Framingham, MA, USA) work- domic) studies with the hope of increasing our understanding of ing in multiple reaction monitoring mode (MRM) was used as a the underlying mechanisms leading to disease. Technological detection system. Selected MRM list was based on research advancements in high-resolution mass spectrometry and rapid papers, databases (e.g. HMDB, METLIN). During analytical improvements in chromatographic techniques have led to quick work-flow, identity verification was found as the most critical expansion of the field of in this research. In this presentation, step. It was performed using enhanced product ion mode (EPI) emphasis is given to the new developments in technologies and supported by a chemical characteristic of analytes (RPLC – their applications in disease biomarker discovery. polarity and SPE – acid-base properties). Results presented in this paper describe three novel aspects of metabolomic research. First, we present an attempt to analyze the metabolic secretome S-39-2 of hMDM exposed to Meth in comparison to non-exposed con- Large-scale label-free clinical proteomics and trol cells. We measured 94 metabolites and identified 11 that were phosphoproteomics for precision medicine significantly different between control and Meth-exposed macro- C. Jimenez phages. Our new analytical approach, utilizing combined C18 OncoProteomics Laboratory, Department of Medical Oncology, and Cogent columns, allowed us to separate and identify OHMA VUmc-Cancer Center Amsterdam, Amsterdam, the Netherlands, isomers. Lastly, we have found two presumably unknown Amsterdam, Netherlands metabolites pending structural determination and confirmation. This work is supported by R01 DA043258 and P30 MH062261 The general goal of our clinical cancer proteomics efforts is to grants from National Institutes of Health (USA). disclose tumor biology and drive improved diagnostics, treatment and management of cancer. To this end, we use label-free mass spectrometry-based proteomics that is optimally suited for large- ShT-39-2 scale clinical sample profiling. I will highlight our work in vari- Development of a diagnostic SARI test system ous cancer types with a focus on exosome proteomics for non- based on protein microchip for detection and invasive diagnostics and phosphoproteomics for response predic- tion. More specifically, I will discuss our prostate cancer effort forecasting the severity of acute respiratory that made use of an innovative workflow for high-throughput infections 1,2 1 1 1 extracellular vesicle proteomics applied to prostate cancer cell A. Taraskin , A. Lozhkov , M. Plotnikova , S. Klotchenko 1 lines and urinary patient samples. Furthermore I will highlight Smorodintsev Research Institute of Influenza, Saint-Petersburg, 2 our newly developed computational analysis approach for Inte- Russia, Peter the Great St. Petersburg Polytechnic University, grative inferred kinase activity (INKA) analysis that can rank Saint-Petersburg, Russia kinase activities in mass spectrometry-based phosphoproteome According to the World Health Organization (WHO), acute res- data derived from single samples. We show that INKA can piratory viral infections cause the overwhelming majority of all uncover oncogenes, differential kinase activity and drug targets. reported infectious diseases, yet methods for their molecular diag- We believe that cancer proteomics powered by precise measure- nosis are limited. The purpose of this study is to develop a multi- ments and dedicated analysis will realize the full potential of mul- parameter diagnostic assay, including a set of reagents, based on ti-parameter diagnostics and personalized medicine. protein microchip technology, which allows personalized diagno- sis of influenza-like illnesses and severe acute respiratory infec- tions (SARI). Ideally, such diagnostics will be capable of determining etiological agents and providing prognostic FEBS Open Bio 9 (Suppl. 1) (2019) 2–64 DOI: 10.1002/2211-5463.12674 63 ª 2019 The Authors. FEBS Open Bio ª 2019 FEBS.
Load more

Recommended publications
  • COVID-19 Evidence Update Date 7Th to 13Th September 2020
    UHB Library & Knowledge Services COVID-19 Evidence Update Date 7th to 13th September 2020 Evidence search Healthcare Databases Advanced Search (HDAS) 1. Medical mask versus cotton mask for preventing respiratory droplet transmission in micro environments. Author(s): Ho, Kin-Fai; Lin, Lian-Yu; Weng, Shao-Ping; Chuang, Kai-Jen Source: The Science of the total environment; Sep 2020; vol. 735 ; p. 139510 Publication Date: Sep 2020 Publication Type(s): Journal Article PubMedID: 32480154 DOI 10.1016/j.scitotenv.2020.139510 Database: MEDLINE 2. Update on neurological manifestations of COVID-19. Author(s): Yavarpour-Bali, Hanie; Ghasemi-Kasman, Maryam Source: Life sciences; Sep 2020; vol. 257 ; p. 118063 Publication Date: Sep 2020 Publication Type(s): Journal Article Review PubMedID: 32652139 Available at Life sciences from Unpaywall Database: MEDLINE 3. Forecasting the Future of Urology Practice: A Comprehensive Review of the Recommendations by International and European Associations on Priority Procedures During the COVID-19 Pandemic. Author(s): Amparore, Daniele; Campi, Riccardo; Checcucci, Enrico; Sessa, Francesco; Pecoraro, Angela; Minervini, Andrea; Fiori, Cristian; Ficarra, Vincenzo; Novara, Giacomo; Serni, Sergio; Porpiglia, Francesco Source: European urology focus; Sep 2020; vol. 6 (no. 5); p. 1032-1048 Publication Date: Sep 2020 Publication Type(s): Journal Article Review PubMedID: 32553544 Available at European urology focus from ClinicalKey You will need to register (free of charge) with Clinical Key the first time you use it. Available at European urology focus from Unpaywall Database: MEDLINE 4. Tongue Ulcers Associated with SARS-COV-2 Infection: A case-series. Author(s): Riad, Abanoub; Kassem, Islam; Hockova, Barbora; Badrah, Mai; Klugar, Miloslav Source: Oral diseases; Sep 2020 Publication Date: Sep 2020 Publication Type(s): Letter PubMedID: 32889763 Available at Oral diseases from Wiley Online Library Medicine and Nursing Collection 2020 Database: MEDLINE 5.
    [Show full text]
  • Issue 1/January, 2006
    Issue 1/January, 2006 by Camilla Krogh Lauritzen, FEBS Information Manager, Editor of FEBS News FEBS Secretariat, co/the Danish Cancer Society Strandboulevarden 49, DK-2100, Denmark E-mail: [email protected] FEBS website: www.FEBS.org Dear Colleagues, A new year has taken its start, and the 2006 FEBS Congress is only approx. six month away. This year, the Con- gress will take place in Istanbul, and again this year, the programme is packed with exiting topics and people — if you have not already done so, have a look at the Congress website, www.FEBS2006.org. Furthermore, please re- member that the FEBS Forum for Young Scientists will take place in connection with the congress (p. 3). 2006 marks "a changing of the guards" in terms of FEBS officers — on page 3 you will get a brief presentation of some known and some new faces in FEBS. Furthermore, you will be presented with the face of Luc Van Dyke (ELSF/ISE), as well as to his article, "Science policy — working together to shape our future". Luc is the debater in this issue of FEBS News, and will elaborate on the current status and importance of science policy science making within Europe (p.9). Finally, this issue will also bring you news from FEBS Letters and FEBS Journal, as well as new opportunities, such as up-coming FEBS courses (p. 8) and job opportunities (p. 10-13). I wish all of you a successful and happy 2006! Kind regards, Camilla About FEBS News: FEBS News is published every second Monday in every second month (starting January).
    [Show full text]
  • Biocreative II.5 Workshop 2009 Special Session on Digital Annotations
    BioCreative II.5 Workshop 2009 Special Session on Digital Annotations The purified IRF-4 was also The main role of BRCA2 shown to be capable of binding appears to involve regulating the DNA in a PU.1-dependent manner function of RAD51 in the repair by by electrophoretic mobility shift homologous recombination . analysis. brca2 irf4 We found that cells ex- Moreover, expression of pressing Olig2, Nkx2.2, and NG2 Carma1 induces phosphorylation were enriched among virus- of Bcl10 and activation of the infected, GFP-positive (GFP+) transcription factor NF-kappaB. cells. carma1 BB I O olig2 The region of VHL medi- The Rab5 effector ating interaction with HIF-1 alpha Rabaptin-5 and its isoform C R E A T I V E overlapped with a putative Rabaptin-5delta differ in their macromolecular binding site within ability to interact with the rsmallab5 the crystal structure. GTPase Rab4. vhl Translocation RCC, bearing We show that ERBB2-dependenterbb2 atf1 TFE3 or TFEB gene fusions, are Both ATF-1 homodimers and tfe3 medulloblastoma cell invasion and ATF-1/CREB heterodimers bind to recently recognized entities for prometastatic gene expression can the CRE but not to the related which risk factors have not been be blocked using the ERBB tyrosine phorbol ester response element. identified. kinase inhibitor OSI-774. C r i t i c a l A s s e s s m e n t o f I n f o r m a t i o n E x t r a c t i o n i n B i o l o g y October 7th - 9th, 2009 www.BioCreative.org BioCreative II.5 Workshop 2009 special session | Digital Annotations Auditorium of the Spanish National
    [Show full text]
  • Accounts of Chemical Research 8 (1975) - 21, 22 {1-11}, 23 - 30 (1997)
    A Accounts of Chemical Research 8 (1975) - 21, 22 {1-11}, 23 - 30 (1997) Acta Chemica Scandinavica 1 (1947) - 27 (1973) : Acta Chemica Scandinavica. 1974 - 1988 : Ser. Aと Ser. B . に分離 A 28 (1974) - A 42 (1988) : Ser. A : Physical and Inorganic Chemistry B 28 (1974) - B 42 (1988) : Ser. B : Organic Chemistry and Biochemistry 43 (1989) : 合併 Acta Chemica Scandinavica. 1 (1947) - 51 (1997) Acta Phytotaxonomica et Geobotanica →APG * Advances in Analytical Chemistry and Instrumentation 1 (1960) - 11 (1973) * Advances in Biological and Medical Physics 10 (1965) - 17 (1980) * Advances in Carbohydrate Chemistry → Advances in Carbohydrate Chemistry and Biochemistry * Advances in Carbohydrate Chemistry and Biochemistry 1 (1945) - 23 (1968) : Advances in Carbohydrate Chemistry 1 (1945) - 61 (2007) 62 (2008) + : 電子ジャーナル * Advances in Catalysis 1 (1948) - 21 (1970) : Advances in Catalysis and Related Subjects 1 (1948) - 41 (1996) * Advances in Catalysis and Related Subjects → Advances in Catalysis * Advances in Chemical Engineering 1 (1956) - 23 (1996) * Advances in Chemical Physics 1 (1958) - 58, 60 - 93, 95 - 96 (1996) * Advances in Clinical Chemistry 1 (1958) - 31 (1994) * Advances in Drug Research 1 (1964) - 12 (1977) * Advances in Electrochemistry and Electrochemical Engineering 1 1 (1961) - 13 (1984) * Advances in Enzyme Regulation 1 (1963) - 33 (1993) * Advances in Enzymology * Advances in Enzymology and Related Subjects * Advances in Enzymology and Related Subjects of Biochemistry → Advances in Enzymology and Related Areas of Molecular Biology
    [Show full text]
  • CRISPER-CAS System and Its Applications
    Bulletin of Environment, Pharmacology and Life Sciences Bull. Env. Pharmacol. Life Sci., Vol 9[9] August 2020 : 172-179 ©2020 Academy for Environment and Life Sciences, India Online ISSN 2277-1808 Journal’s URL:http://www.bepls.com CODEN: BEPLAD Global Impact Factor 0.876 Universal Impact Factor 0.9804 NAAS Rating 4.95 REVIEW ARTICLE OPEN ACCESS CRISPER-CAS System and Its Applications Devyani Jogran* , Jeetendra Singh Bohra and Pushpa Lohani Department of Molecular Biology and Genetic Engineering, College of Basic Science and Humanities G.B Pant University of Agriculture and Technology, Pantnagar, Uttarakhand *corresponding author email : [email protected] ABSTRACT The CRISPR-Cas focuses on adaptive immunity systems of many bacteria and nearly all archaea. Its discovery has proven it as a simple tool and its effectiveness for many aspects like Transcription Activator. It can be used to add desirable and remove undesirable alleles simultaneously in a single event. Presently CRISPR-Cas has emerged as a engineering tool to controlled genetic modification in many organisms like Staphylococcus aureus, Escherichia coli, Saccharomyces cerevisiae etc. CRISPR-Cas9 system has revolutionized the area of genome editing because of easy laboratory construction, targeting multiple genomic sites. The Cas9 enzyme has been used as a popular tool for directed gene editing used in medical research areas. It can be used as an effective gene therapy method in various genetic disorders where no curative treatment is available. Mainly it is used in microbial adaptive immune system, gene regulations, functional genomics, genome editing, Keywords: Genome editing, CRISPR-Cas Received 21.05.2020 Revised 15.06.2020 Accepted 23.07.2020 INTRODUCTION In 1970, recombinant DNA technology development marked the beginning of new era in biology.
    [Show full text]
  • 0 WILEY and MAYNOOTH UNIVERSITY WILEY READ AND
    WILEY and MAYNOOTH UNIVERSITY ________________________________________ WILEY READ AND PUBLISH AGREEMENT ________________________________________ 0 THIS AGREEMENT is made on the 15th day of March, 2021 BETWEEN: John Wiley & Sons, Inc., a New York corporation, 111 River Street, Hoboken, New Jersey 07030, and its affiliates Wiley Periodicals LLC, John Wiley & Sons, Ltd, John Wiley & Sons Australia, Ltd, Wiley-VCH GmbH, John Wiley & Sons A/S, collectively “Wiley” or “Publisher” AND National University of Ireland Maynooth, Maynooth University, whose principal address is at Maynooth, Co Kildare, Ireland (“Maynooth University”), acting on its own behalf and as non-exclusive agent on behalf of the other Members of the Consortium. RECITALS WHEREAS Maynooth University has been appointed by Members of the Consortium, as their non-exclusive agent, to enter into agreements on the Members’ behalf for accessing electronic educational and research resources; AND WHEREAS the Publisher provides Wiley Online Library which is an electronic collection of online journals, books, and research resources, covering life, health, social, and physical sciences, and the Publishing Privilege that gives authors the option to publish articles on an open access basis in select Wiley journals.; AND WHEREAS Maynooth University wishes to enter into this Agreement in order for Members of the Consortium to be authorised to access and use the Licensed Material; AND WHEREAS the Consortium and the Publisher share the goal to transition to an open access model and the transition to full open access will include continued access to the Publisher’s journal content, AND WHEREAS the parties are desirous to contract on the basis of the terms and conditions of this Agreement.
    [Show full text]
  • For Professor KELVIN J. A. DAVIES Full Name: Kelvin James Anthony Davies, Ph.D., D.Sc
    CVKJADnov2020 CURRICULUM VITAE for Professor KELVIN J. A. DAVIES Full Name: Kelvin James Anthony Davies, Ph.D., D.Sc. Appointment: The University of Southern California • Executive Vice Dean (Dean of Faculty & Academic affairs and Dean of Research) of the Leonard Davis School of Gerontology, • Director, Ethel Percy Andrus Gerontology Center, • Director, USC Free Radical Institute, • James E. Birren Chair of Gerontology, Leonard Davis School of Gerontology, • USC Distinguished Professor of Gerontology, Molecular & Computational Biology; and Biochemistry & Molecular Medicine (Leonard Davis School of Gerontology; Dornsife College of Letters, Arts & Sciences; and Keck School of Medicine of USC). Work Address: The Ethel Percy Andrus Gerontology Center, University of Southern California, 3715 McClintock Avenue, Los Angeles, California 90089-0191, U.S.A. Work Contact: e-mail: [email protected] Phone: (213)740-8959 Citizenships: U.S.A. (citizenship 1993) and Great Britain (born in London, England) Spouse: Joanna M. S. Davies, M.D., FACP Google Scholar Metrics: h-index 110, i10-index 226, Citations 47,870 Education: Liverpool & Lancaster Universities B.Ed. 1974 General Science & Kinesiology University of Wisconsin B.S. 1976 Physiology & Biophysics University of Wisconsin M.S. 1977 Physiology & Biophysics University of California, Berkeley C.Phil. 1979 Biochemistry & Physiology University of California, Berkeley Ph.D. 1981 Biochemistry & Physiology University of Southern California post doc. 1981 Biochemistry & Molecular Toxicology Harvard Medical
    [Show full text]
  • Author Guidelines Information About FEBS Open Bio
    Author Guidelines Information about FEBS Open Bio .......................................................................................................... 1 Editorial Policies ............................................................................................................................................. 2 Types of manuscripts .................................................................................................................................... 4 Preparing your manuscript ....................................................................................................................... 5 After Acceptance .......................................................................................................................................... 12 Frequently asked questions ..................................................................................................................... 13 Information about FEBS Open Bio Aims and Scope FEBS Open Bio is an online-only open access journal for the rapid publication of research articles in molecular and cellular life sciences in both health and disease. The journal's peer review process focuses on the technical soundness of papers, leaving the assessment of their impact and importance to the scientific community. FEBS Open Bio publishes experimental findings, critical analysis, methodological and technical innovations, and hypotheses. Novel or innovative work is encouraged, but papers describing sound science of a confirmatory nature in developing fields or extending
    [Show full text]
  • Issue 3 (November) 2014
    ISSUE 3 (NOVEMBER) 2014 40th FEBS Congress FEBS programmes: FEBS–EMBO 2014 FEBS publications FEBS community updates conference round-up news Page 4 Page 8 Page 12 Page 26 Page 35 CONTENTS Contents: Key upcoming dates for Preface 3 FEBS activities FEBS Programmes: updates 40th FEBS Congress 40th FEBS Congress, Berlin, 2015 4 4–9 July 2015 FEBS Advanced Courses 8 Abstract submission deadline: 2 March 2015 FEBS Education Activities 11 Bursary application deadline: 2 March 2015 Early-bird registration deadline: 12 March 2015 FEBS–EMBO 2014 Conference Round-up www.febs2015.org The FEBS–EMBO 2014 Conference 12 FEBS Awards 14 FEBS Young Scientists’ Forum FEBS Workshops and Events 17 2–4 July 2014 FEBS Young Scientists’ Forum 2014 22 Application deadline: 31 January 2015 bit.ly/YSF2015 FEBS Fellows Meeting 2014 24 FEBS 50th Anniversary Dinner 25 FEBS Advanced Courses Applications for 2016 course funding: 1 March 2015 FEBS Publications Applications to participate in 2015 courses: see FEBS Publications at FEBS–EMBO 2014 26 individual course deadlines Digital Developments 28 www.febs.org/our-activities/advanced- Journal Highlights and Special Issues 33 courses/2015-advanced-courses FEBS Community News FEBS – Biochemical Society FEBS-sponsored Lectures 35 Education Workshop Obituary 38 FEBS Education Workshop bursaries deadline: FEBS Council: Elections 39 1 December 2014 Abstract submission deadline: 26 January 2015 Scientific Events Calendar 40 www.febs.org/our-activities/education Cover: Berlin, at the heart of the FEBS area, is the location for the 2015 FEBS Congress, hosted this time by the German Society for Biochemistry and Molecular Biology. Registration and abstract submission for the Congress have opened, and the event is introduced on pages 4–7 of this issue of FEBS News.
    [Show full text]
  • Long Timescale Dynamics of Cholesterol in Lipid Bilayers
    Long Timescale Dynamics of Cholesterol in Lipid Bilayers Proposal to the Biomedical Applications Group at the Pittsburgh Supercomputing Center, funded by the National Institute of General Medical Science June 23, 2016 Summary Cholesterol, the ubiquitous sterol present in mammalian cells, is a key player in maintaining and modifying characteristics of cell membranes, modulating the function of membrane-embedded and peripheral proteins. Cholesterol concentrations are cell type dependent, dynamic, and tightly regulated. Despite decades of experimental and computational studies, due to the fluidity and heterogeneity of the membrane environment, fundamental aspects of cholesterol function and dynamics are not yet understood. We propose to combine long timescale molecular dynamics with state-of-the-art magic-angle spinning solid-state NMR (SSNMR) experiments to yield an atomistically-resolved understanding of cholesterol. We have developed isotopic labeling and customized SSNMR measurements to provide site-resolved chemical shifts, order parameters and relaxation rates, which are experimental parameters dependent upon the hierarchical dynamics of the sterol in true lipid bilayers. These highly precise experimental data sets, when synergistically combined with computational analysis leveraging the unprecedented computational power of Anton 2, will enable a major breakthrough in understanding the molecular interactions of cholesterol in membranes. Our major goals are to use the long timescale MD simulations to discern for the first time the molecular interactions that lead to the hierarchical cholesterol-lipid and cholesterol-cholesterol dynamics. PI: Chad M. Rienstra Professor of Chemistry University of Illinois at Urbana-Champaign 600 South Mathews Avenue, Urbana, IL 61801 Telephone: (217) 244-4655 FAX: (217) 244-3186 Email: [email protected] Co-PI: Taras V.
    [Show full text]
  • (September) 2013
    ISSUE 3 (SEPTEMBER) 2013 38th FEBS Congress FEBS programmes: FEBS community FEBS publications Scientific events round-up updates news calendar Page 3 Page 16 Page 20 Page 22 Page 27 CONTENTS Key upcoming dates for FEBS activities Contents: FEBS Congress Round-up FEBS–EMBO 2014 Conference 30 August – 4 September 2014 The 38th FEBS Congress 3 Abstract submission from December 2013 FEBS Medals and Awards 6 Registration from January 2014 FEBS Young Scientists’ Forum 8 www.febs-embo2014.org FEBS Congress Workshops 9 FEBS Congress Science and Society Lecture 12 FEBS Young Scientists’ Forum 27–30 August 2014 FEBS Programmes: updates Applications: 8 December 2013 – 31 March 2014 FEBS Advanced Courses 2014 16 www.febs-embo2014.org FEBS Education Workshops 17 FEBS–EMBO 2014 Conference, and FEBS YSF 18 FEBS Advanced Courses Applications for 2015 course funding: 1 March 2014 FEBS Community News Applications to participate in 2014 courses: see Spanish (SEBBM) Society 20 individual course deadlines Polish Biochemical Society 21 www.febs.org/index.php?id=86 FEBS Publications FEBS Fellowships FEBS Journal 22 Application deadlines: FEBS Letters 24 Long-Term and Return-to-Europe Fellowships: 1 October 2013, then 1 October 2014 Molecular Oncology 25 Summer Fellowships: 1 April 2014 FEBS Open Bio 26 Follow-up Research Fund (for FEBS Fellows): 1 April 2014 Applications for other Fellowships can be 27 Scientific Events Calendar submitted throughout the year Career Opportunities 28 www.febs.org/index.php?id=81 Cover: While this issue of FEBS News reports on the 2013 FEBS Congress in St Petersburg (pages 3–5), plans are already under way for next year’s big event – a joint anniversary conference with EMBO (the FEBS–EMBO 2014 Conference), hosted by the French Society for Biochemistry and Molecular Biology (see pages 18–19).
    [Show full text]
  • 2021-FEBS Internship
    Internship: Editorial Associate (virtual) The Federation of European Biochemical Societies (FEBS https://www.febs.org/) runs four scientific journals: The FEBS Journal, FEBS Letters, FEBS Open Bio and Molecular Oncology. The postholder would work with our editorial office staff, gaining insight into the publication process of academic research and assisting with the promotion of our journals to the scientific community. A range of projects are available, depending on the interests of the postholder, with some examples given below. • Supporting the journal editors with triage of submitted manuscripts and the selection of suitable reviewers • Assisting in the quality control of provisionally accepted manuscripts, screening figures for possible signs of image manipulation • Promotion of our journals through our own FEBS Network (https://network.febs.org/)and on social media • Assisting with data analysis related to journal performance and article dissemination • Research and compilation of ‘virtual’ collections of published articles • Assisting with the commissioning and writing of ‘front half’ review and editorial content The postholder will have the opportunity to suggest and embark on projects of their own in consultation with the journal editorial staff. About FEBS and FEBS Press FEBS is a charitable organization, supporting research and education in molecular life sciences through its journals, fellowships, courses, congress and other activities. It brings together the thousands of members of national biochemistry and molecular biology societies in Europe and neighbouring regions. The publication of high-quality journals by scientists for scientists is one of FEBS’ core objectives, with the revenue raised supporting fellowships, courses, congresses and other activities. FEBS Press was established in 2016 – in partnership with Wiley, a publisher renowned for its society support – to better integrate its four journals with other FEBS services, and to ensure seamless introduction of new initiatives for all its authors and readers.
    [Show full text]